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PCardiac Sympathetic Denervation Assessed With
123-Iodine Metaiodobenzylguanidine Imaging
Predicts Ventricular Arrhythmias in
Implantable Cardioverter-Defibrillator Patients
Mark J. Boogers, MD,*‡ C. Jan Willem Borleffs, MD,* Maureen M. Henneman, MD,*
Rutger J. van Bommel, MD,* Jan van Ramshorst, MD,* Eric Boersma, PHD,§
Petra Dibbets-Schneider, MSC,† Marcel P. Stokkel, MD, PHD,† Ernst E. van der Wall, MD, PHD,*
Martin J. Schalij, MD, PHD,* Jeroen J. Bax, MD, PHD*
Leiden, Utrecht, and Rotterdam, the Netherlands
Objectives The purpose of this study was to evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging
predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator (ICD) therapy (primary
end point) and the composite of appropriate ICD therapy or cardiac death (secondary end point).
Background Although cardiac sympathetic denervation is associated with ventricular arrhythmias, limited data are available
on the predictive value of sympathetic nerve imaging with 123-I MIBG on the occurrence of arrhythmias.
Methods Before ICD implantation, patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 123-I
MIBG (planar and single-photon emission computed tomography [SPECT]) imaging was performed to assess car-
diac innervation (heart-to-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-
rest myocardial perfusion imaging was performed to assess myocardial infarction and perfusion abnormalities
(perfusion defect scores). During follow-up, appropriate ICD therapy and cardiac death were documented.
Results One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. During a mean follow-up of
23  15 months, appropriate ICD therapy (primary end point) was documented in 24 (21%) patients and appro-
priate ICD therapy or cardiac death (secondary end point) in 32 (28%) patients. Late 123-I MIBG SPECT defect
score was an independent predictor for both end points. Patients with a large late 123-I MIBG SPECT defect
(summed score 26) showed significantly more appropriate ICD therapy (52% vs. 5%, p  0.01) and appropri-
ate ICD therapy or cardiac death (57% vs. 10%, p  0.01) than patients with a small defect (summed score
26) at 3-year follow-up.
Conclusions Cardiac sympathetic denervation predicts ventricular arrhythmias causing appropriate ICD therapy as well as the
composite of appropriate ICD therapy or cardiac death. (J Am Coll Cardiol 2010;55:2769–77) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.066w
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sudden cardiac death (SCD) represents a leading cause of
eath in the developed world with an estimated annual
ncidence of 300,000 to 350,000 patients in the U.S. (1).
mplantable cardioverter-defibrillator (ICD) treatment is
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009, accepted December 2, 2009.ell established in patients at high risk for arrhythmic
eath. Initially, ICD treatment was indicated in survivors of
ustained ventricular tachycardia or ventricular fibrillation,
nd more recently, in a population at high risk, regardless of
rior ventricular tachyarrhythmias (2,3). Based on large
andomized trials, current guidelines recommend ICD
reatment based solely on a poor left ventricular (LV)
ystolic function with or without nonsustained ventricular
achycardia as a class I indication (4).
Post-hoc analysis of the second MADIT II (Multicenter
utomated Defibrillator Implantation Trial) population
howed that only 35% of patients received appropriate ICD
herapy after 3-year follow-up (5). Additionally, the major-
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a population without ICD indi-
cation (6). Although the benefits
of ICD treatment have been
demonstrated, the question has
been raised whether improve-
ments in patient selection can be
made.
Dysfunction of the autonomic
nervous system (which can be as-
sessed with 123-iodine metaiodo-
benzylguanidine [123-I MIBG]
imaging) is thought to play an
important role in the develop-
ment of ventricular tachyarrhyth-
mias (7,8). Observational studies
have demonstrated that cardiac
denervation (as evidenced by re-
duced 123-I MIBG uptake) is
associated with the occurrence of
ventricular tachyarrhythmias (9,10).
Moreover, it was recently shown
that inducibility of ventricular
tachyarrhythmias is related to re-
gional cardiac sympathetic de-
nervation as assessed with 123-I
MIBG imaging (10).
At present, limited data are
available on the role of 123-I
IBG imaging for prediction of ventricular arrhythmias.
oreover, the value of 123-I MIBG imaging in identifica-
ion of patients who may benefit from ICD treatment is
nclear. Accordingly, this study evaluated the role of cardiac
ympathetic nerve imaging with 123-I MIBG for the
rediction of ventricular arrhythmias causing appropriate
CD therapy (primary end point) and the composite of
ppropriate ICD therapy or cardiac death (secondary end
oint).
ethods
atient population and protocol. The patient population
onsisted of consecutive advanced heart failure patients
ndergoing cardiac 123-I MIBG imaging for heart failure
isk stratification. The patients were clinically referred for
CD implantation based on poor LV function with or
ithout nonsustained ventricular tachycardia (primary pre-
ention) or prior sustained ventricular tachycardia or ven-
ricular fibrillation (secondary prevention) (4).
Prior to ICD implantation, patients underwent 123-I
IBG imaging and gated myocardial perfusion single-
hoton emission computed tomography (SPECT) imaging
ith 99m-technetium (Tc) tetrofosmin. 123-I MIBG im-
ging was clinically performed to assess cardiac sympathetic
nnervation for risk stratification of heart failure patients
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
CAD  coronary artery
disease
CI  confidence interval
CRT  cardiac
resynchronization therapy
H/M ratio  heart-to-
mediastinum ratio
HR  hazard ratio
ICC  intraclass
correlation coefficients
ICD  implantable
cardioverter-defibrillator
123-I MIBG  123-iodine
metaiodobenzylguanidine
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
SCD  sudden cardiac
death
SPECT  single-photon
emission computed
tomography
Tc  technetium11). Stress-rest myocardial perfusion imaging was per- Sormed to assess myocardial infarction (location and extent)
nd perfusion abnormalities (ischemia). All patients re-
eived optimal pharmacologic and revascularization therapy
rior to ICD implantation. Patient’s medication was con-
inued during cardiac imaging.
During follow-up, ventricular arrhythmia with subse-
uent ICD therapy (appropriate ICD therapy) and cardiac
ortality were documented. The occurrence of primary end
oints (appropriate ICD therapy) and secondary end points
the composite of appropriate ICD therapy or cardiac death)
as assessed for all patients. Subsequently, the value of
23-I MIBG and myocardial perfusion imaging variables in
he prediction of endpoints was studied.
23-I MIBG imaging. Patients were pre-treated with 120
g of sodium iodide to block uptake of free iodine-123 by
he thyroid gland. Sodium iodide was given orally 1 h before
ntravenous administration of 185 MBq 123-I MIBG
Adreview, General Electric Healthcare). 123-I MIBG
lanar and SPECT imaging was performed in supine
osition. A 10-min planar image was acquired from an
nterior thoracic view (256 256 matrix) 10 to 15 min after
racer administration.
Thereafter, a SPECT study (step and shoot mode, 90
rojections, imaging time 30 min) was performed using a
ual-head camera system (GCA-7200, Toshiba Corp.,
okyo, Japan) equipped with low-energy, parallel-hole,
igh-resolution collimators. A 128  128 matrix was used
or SPECT studies, and a 20% energy peak was centered
round the 159-keV energy peak of 123-I MIBG. Planar
nd SPECT imaging were repeated after 3 to 4 h of tracer
dministration.
Heart-to-mediastinum (H/M) ratio was calculated from
lanar imaging using regions of interest placed over the
ntire heart and upper mediastinum (7  7 pixels) (10).
123-I MIBG SPECT studies were processed with fil-
ered back-projection and reconstructed into standard long-
nd short-axis, perpendicular to the heart axis (12). Three
ate SPECT studies were uninterpretable and excluded from
valuation of late 123-I MIBG SPECT imaging.
From planar images, the H/M ratio was computed by
ividing the mean counts per pixel within the myocardium
y the mean counts per pixel within the mediastinum. H/M
atio was computed for early and late planar imaging.
ardiac washout rate was calculated using the following
ormula: [(early H/M ratio)  (delayed H/M ratio)]/(early
/M ratio)  100. No background correction was per-
ormed in this study.
From SPECT images, the 123-I MIBG SPECT defect
core was calculated by assessment of patient’s segmental
23-I MIBG tracer uptake score using the 17-segment
odel (12). Each myocardial segment was scored according
o the following tracer uptake scale: 0  normal tracer
ptake; 1  mildly reduced tracer uptake; 2  moderately
educed tracer uptake; 3  severely reduced tracer uptake;
nd 4  no tracer uptake. Subsequently, the 123-I MIBG
PECT defect score was calculated by the summation of
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June 15, 2010:2769–77 Cardiac Denervation Predicts Arrhythmiaegmental tracer uptake scores. The 123-I MIBG SPECT
efect score was calculated for early and delayed SPECT
maging. Data analysis was performed by 2 blinded and
ndependent observers. Both readers scored all study seg-
ents, and disagreements were resolved by consensus.
here was no association between the myocardial perfusion
nd 123-I MIBG SPECT images, as the different SPECT
mages were evaluated in separate sessions.
Reproducibility of the scoring system was evaluated by
ssessment of intraobserver and interobserver variability. To
ssess intraobserver variability, myocardial segments were
cored twice by the same observer in a subset of 30 randomly
elected patients. To assess interobserver variability, the
econd SPECT reader independently graded the myocardial
egments from the same subset of patients.
ated myocardial perfusion SPECT. Stress-rest gated
yocardial perfusion SPECT imaging with Tc tetrofosmin
500 MBq, MYOVIEW, General Electric Healthcare) was
erformed as previously described (13). Myocardial perfu-
ion images were analyzed by 2 observers who were blinded
o 123-I MIBG images.
The myocardium was divided into 17 segments, and the
atient’s segmental perfusion score was assessed using a
imilar tracer uptake scale as used for 123-I MIBG images
12). The rest perfusion defect score was calculated by
ummation of segmental perfusion scores on resting myo-
ardial perfusion imaging. Stress perfusion defect score was
alculated by summation of segmental perfusion scores on
tress myocardial perfusion imaging. Accordingly, both rest
nd stress perfusion defect scores could range from 0 to 68
17  4) points. Subsequently, the summed perfusion
ifference score (indicating the extent of reversible myocar-
ial perfusion defects) was calculated by subtracting the rest
erfusion defect score from the stress perfusion defect score.
inally, the 123-I MIBG/perfusion mismatch score was
alculated by subtracting the rest perfusion defect score from
he late 123-I MIBG SPECT defect score.
CD implantation. ICDs were implanted transvenously
nd without thoracotomy. Testing of sensing and pacing
hresholds and defibrillation threshold testing was per-
ormed during implantation. In case of patient eligibility for
ardiac resynchronization therapy (CRT), a combined
RT-D device was implanted (14).
linical follow-up and end points. Clinical follow-up was
erformed by evaluation of device interrogation printouts
nd patient medical record data every 3 to 6 months.
The primary end point was defined as the occurrence of
ppropriate ICD therapy. Appropriate ICD therapy was
efined as antitachycardia pacing (ATP) or shock triggered
y ventricular tachycardia or ventricular fibrillation. ICD
ischarges were evaluated at the outpatient pacemaker clinic
sing ICD-stored electrocardiographic data by 2 experi-
nced electrophysiologists, blinded to other study data.
The secondary end point was a combined end point
onsisting of appropriate ICD therapy or cardiac death. iardiac mortality included death caused by progressive
eart failure or acute myocardial infarction.
tatistical analysis. Continuous variables are expressed as
ean  SD, and categorical data are expressed in numbers
nd percentages. Intra- and interobserver agreements were
valuated by calculating the intraclass correlation coefficients
ICC). Excellent agreement was defined as an intraclass
orrelation coefficient of 0.8. Cox proportional hazards
egression analysis was performed to evaluate which vari-
bles were associated with the primary or secondary end
oint. At first, univariable analysis of baseline characteristics
as performed to determine significant predictors for both
nd points. All variables that were significantly associated
ith the primary or secondary end point at the p  0.15
evel were included in a multivariable analysis. When early
nd late 123-I MIBG imaging variables showed strong
nterrelation (Pearson’s correlation coefficient 0.8), early
23-I MIBG imaging variables were excluded from multi-
ariable analysis. Only late 123-I MIBG imaging variables
ere included in the multivariable analysis as they are the
ost commonly used 123-I MIBG imaging parameters
11). For each variable, a hazard ratio (HR) with a 95%
onfidence interval (CI) was calculated.
Cumulative event rates were assessed using the method of
aplan-Meier and log-rank test. Additionally, late 123-I
IBG SPECT defect score was subdivided using the
rospectively selected median value as a cutoff. The median
alue was selected to ensure that the number of patients was
qually distributed across the two groups. Furthermore,
eceiver-operating characteristic (ROC) curve analysis was
erformed to determine the optimal cutoff point of the
23-I MIBG SPECT defect score for prediction of appro-
riate ICD therapy. The optimal cutoff point was defined as
he highest sum of sensitivity and specificity. All analyses
ere 2-sided, and a p value 0.05 was considered statisti-
ally significant. Statistical analyses were performed with
PSS software package, version 15.0 (SPSS Inc., Chicago,
llinois).
esults
atient population. A total of 116 patients (80 men, mean
ge 65  9 years) were enrolled. Baseline characteristics of
ll patients are summarized in Table 1. One hundred three
89%) patients received an ICD as primary prevention, and
3 (11%) patients as secondary prevention for SCD. Eighty-
ix (74%) patients were diagnosed with ischemic cardiomyo-
athy, and 30 (26%) patients with nonischemic cardiomyo-
athy. The mean New York Heart Association (NYHA)
unctional class was 2.9  0.6, and the mean left ventricular
jection fraction (LVEF) was 28  8%. A combined
RT-D device was implanted in 101 patients. Medication
onsisted of beta-blockers (71% of patients), amiodarone
19% of patients), angiotensin-converting enzyme inhibitors
r angiotensin II antagonists (85% of patients), and diuret-
cs (88% of patients).
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Cardiac Denervation Predicts Arrhythmia June 15, 2010:2769–7723-I MIBG and myocardial perfusion imaging. Base-
ine variables of 123-I MIBG and myocardial perfusion
maging are shown in Table 2. Mean values of early and late
/M ratio were 1.58  0.18 and 1.47  0.18, respectively.
ccordingly, the mean value of cardiac washout rate was
.80  6.37. Furthermore, the early 123-I MIBG SPECT
efect score had a mean value of 21.6  10.1, and the late
23-I MIBG SPECT defect score had a mean value of
6.8  10.0.
The mean rest perfusion defect score was 16.8  10.3,
hereas the mean stress perfusion defect score was 18.3 
0.6. Accordingly, the mean summed perfusion difference
core was 1.4  2.8.
The mean 123-I MIBG/perfusion mismatch score was
.9  12.3, indicating larger 123-I MIBG defects as
ompared with perfusion defects (26.8  10.0 vs. 16.8 
0.3, p  0.01).
An excellent reproducibility was observed for early (ICC:
.98, 95% CI: 0.94 to 0.99) and late (ICC: 0.98, 95% CI:
.95 to 0.99) 123-I MIBG SPECT defect score. Further-
ore, both SPECT readers showed an excellent agreement
or early (ICC: 0.97, 95% CI: 0.95 to 0.99) and late (ICC:
.98, 95% CI: 0.96 to 0.99) 123-I MIBG SPECT defect
core.
Figure 1 shows an example of normal resting myocardial
erfusion with a defect on late 123-I MIBG SPECT
maging in a patient who received appropriate ICD therapy
aseline Characteristics ofhe Study Population (n  116)Table 1 B sel ne Characteristics ofthe Study Population (n  116)
Characteristics Values
Age (yrs) 65 9
Male sex 80 (69)
CRT-D 101 (87)
ICD indication
Primary prevention 103 (89)
Secondary prevention 13 (11)
Ischemic cardiomyopathy 86 (74)
NYHA functional class 2.9 0.6
LVEF (%) 28 8
Cardiovascular risk factors
Diabetes 16 (14)
Hypertension 37 (32)
Hypercholesterolemia 30 (26)
Smoking 31 (27)
Family history of CAD 35 (30)
Medication use
Beta-blocker 82 (71)
Amiodarone 22 (19)
ACE-I/ATII antagonist 98 (85)
Oral anticoagulant 76 (66)
Statin 79 (68)
Diuretic 102 (88)
ata are represented as mean  SD or as n (%).
ACE-I  angiotensin-converting enzyme inhibitor; AT  angiotensin; CAD  coronary artery
isease; CRT-D  cardiac resynchronization therapy defibrillator; ICD  implantable cardioverter-
efibrillator; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association.fter 18 months of follow-up. Srimary end point: appropriate ICD therapy. During
3  15 months follow-up, 86 episodes of ventricular
achycardia or ventricular fibrillation were terminated by
ppropriate ICD therapy in 24 (21%) patients. Appropriate
CD therapy consisted of 44 episodes of ATP in 16 (14%)
atients and 42 ICD shocks in 15 (13%) patients.
Univariable analyses demonstrated that ICD indication
secondary vs. primary prevention), ischemic cardiomyopa-
hy, early 123-I MIBG SPECT defect score, late 123-I
IBG SPECT defect score, summed perfusion difference
core, and the 123-I MIBG/perfusion mismatch score were
ignificantly associated with appropriate ICD therapy
Table 3). The early 123-I MIBG SPECT defect score was
xcluded for multivariable analysis as it showed strong
nterrelation (r  0.82) with the late 123-I MIBG SPECT
efect score.
Subsequently, multivariable analysis demonstrated that
CD indication (secondary vs. primary prevention) (HR:
.85, 95% CI: 1.43 to 10.37, p  0.01) and late 123-I
IBG SPECT defect score (HR: 1.13, 95% CI: 1.05 to
.21, p 0.01) were independent predictors for appropriate
CD therapy.
isk stratification for appropriate ICD therapy. Patients
ere stratified according to the prospectively selected me-
ian value of the 123-I MIBG SPECT defect score
summed score of 26) into patients with large (summed
core 26) or small (summed score 26) late 123-I MIBG
PECT defect. Twenty-two (40%) patients with a large late
23-I MIBG SPECT defect (summed score 26) versus 2
3%) patients with a small late 123-I MIBG SPECT defect
summed score 26) received appropriate ICD therapy
p  0.01).
The cumulative event rate at 3-year follow-up for appro-
riate ICD therapy was 52% (95% CI: 36% to 68%) for
atients with a large late 123-I MIBG SPECT defect versus
% (95% CI: 0% to 11%) for patients with a small late 123-I
IBG SPECT defect (Fig. 2). Appropriate ICD therapy
as significantly more often documented in patients with a
aseline Variables of 123-I MIBGnd Myocardi l Perfusion ImagingTable 2 Bas line Variables of 123-I MIBGand Myocardial Perfusion Imaging
123-I MIBG imaging
Early planar H/M ratio 1.58 0.18
Late planar H/M ratio 1.47 0.18
Cardiac washout rate (%) 6.80 6.37
Early 123-I MIBG SPECT defect score 21.6 10.1
Late 123-I MIBG SPECT defect score 26.8 10.0
Myocardial perfusion imaging
Rest perfusion defect score 16.8 10.3
Stress perfusion defect score 18.3 10.6
Summed perfusion difference score 1.4 2.8
123-I MIBG/perfusion mismatch score 9.9 12.3
ata are represented as mean  SD.
H/M ratio  heart-to-mediastinum ratio; 123-I MIBG  123-iodine metaiodobenzylguanidine;
PECT  single-photon emission computed tomography.
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June 15, 2010:2769–77 Cardiac Denervation Predicts Arrhythmiaarge late 123-I MIBG SPECT defect when compared with
atients with a small late 123-I MIBG SPECT defect
uring a mean follow-up of 23  15 months (log-rank test,
 0.01). Moreover, the risk for appropriate ICD therapy
as 13 times higher in patients with a large late 123-I
IBG SPECT defect as compared with patients with a
mall defect (HR: 12.81, 95% CI: 3.01 to 54.50, p  0.01).
ROC curve analysis showed an excellent predictive value
f late 123-I MIBG SPECT defect score (area under the
urve: 0.87). The optimal cutoff value of 123-I MIBG
PECT defect score was defined at 31, which yielded a
ensitivity of 75% and a specificity of 82% for prediction of
ppropriate ICD therapy. Patients with large 123-I MIBG
PECT defects (31) showed significantly more appropri-
te ICD therapy as compared with patients with small late
23-I MIBG SPECT defects (31) at 3-year follow-up
9% vs. 66%, p  0.01).
econdary end point: appropriate ICD therapy or cardiac
ortality. Appropriate ICD therapy or cardiac mortality
as documented in 32 (28%) patients. In total, 24 (21%)
atients received appropriate ICD therapy, and 8 (7%)
atients died of progressive heart failure without previous
ppropriate ICD therapy. In total, cardiac death was doc-
mented in 13 (11%) patients, including 5 (4%) patients
ho received appropriate ICD therapy before cardiac death.
Univariable analysis demonstrated that ICD indication
secondary vs. primary prevention), ischemic cardiomyopa-
hy, delayed H/M ratio, early 123-I MIBG SPECT defect
core, late 123-I MIBG SPECT defect score, and 123-I
IBG/perfusion mismatch score were significant predic-
ors for the secondary end point. Since early and late 123-I
IBG SPECT defect scores were strongly interrelated (r
.82), early 123-I MIBG SPECT defect score was excluded
Figure 1 Example of Resting Myocardial Perfusion and Late 12
In this patient, showing normal myocardial perfusion and abnormal 123-iodine me
defibrillator therapy (antitachycardia pacing) was documented after 18 months of for multivariable analysis. lLate 123-I MIBG SPECT defect score (HR: 1.12, 95%
I: 1.05 to 1.19, p  0.01) was the only independent
redictor in multivariable analysis.
isk stratification for appropriate ICD therapy or cardiac
ortality. Appropriate ICD therapy or cardiac mortality
as documented in 28 (51%) patients with a large late 123-I
IBG SPECT defect (summed score 26) and in 4 (7%)
atients with a small late 123-I MIBG SPECT defect
summed score 26) (p  0.01).
The cumulative event rate at 3-year follow-up for appro-
riate ICD therapy or cardiac mortality was 57% (95% CI:
3% to 72%) for patients with a large late 123-I MIBG
PECT defect as compared to 10% (95% CI: 0% to 20%)
or patients with a small defect. Appropriate ICD therapy or
ardiac death was significantly more documented in patients
ith a large late 123-I MIBG SPECT defect as compared
ith patients with a small defect during a mean follow-up of
3  15 months (log-rank test, p  0.01). Moreover, the
isk for appropriate ICD therapy or cardiac death was 8
imes higher in patients with a large late 123-I MIBG
PECT defect than in patients with a small defect (HR:
.29, 95% CI: 2.91 to 23.63, p  0.01).
iscussion
he main findings of the study can be summarized as
ollows. Late 123-I MIBG SPECT defect score was an
ndependent predictor for ventricular arrhythmias causing
ppropriate ICD therapy (primary end point) as well as the
omposite of appropriate ICD therapy or cardiac death
secondary end point). In addition, cumulative event rates
or appropriate ICD therapy (52% vs. 5%, p  0.01) and
ppropriate ICD therapy or cardiac death (57% vs. 10%,
 0.01) were significantly higher in patients with a large
IBG Imaging in an ICD Patient
benzylguanidine (123-I MIBG) imaging, an appropriate implantable cardioverter-
p. (A) Resting myocardial perfusion imaging. (B) Late 123-I MIBG imaging.3-I M
taiodo
ollow-uate 123-I MIBG SPECT defect (summed score 26) as
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Cardiac Denervation Predicts Arrhythmia June 15, 2010:2769–77ompared with patients with a small late 123-I MIBG
PECT defect (summed score 26) at 3-year follow-up.
mportantly, only 2 (3%) patients with a small late 123-I
IBG SPECT defect received appropriate ICD therapy
uring follow-up.
CD and substrate imaging. ICD therapy has become a
ornerstone treatment in patients at high risk for sudden
rrhythmic death (4). Although the benefits of ICD treat-
ent have been demonstrated, the question has been raised
hether patient selection according to the current guide-
ines is adequate, as it is still unclear which patients will
enefit from ICD treatment (2,3,5). Post-hoc analysis of
he MADIT II (Second Multicenter Automated Defibril-
ator Implantation Trial) population demonstrated that 35%
f patients received appropriate ICD therapy after 3-year
ollow-up (5). Moreover, it has been shown that the
ajority of arrhythmic deaths occurs in patients without
Univariable and Multivariable Analyses of Baselifor Appropri te ICD The apy (Primary End Point)Table 3 Univariabl nd Multivariable Analyfor Appropriate ICD Therapy (Primar
H
Age (yrs) 1.02
Male sex 1.52
CRT-D 1.15
ICD indication (secondary vs. primary prevention) 4.55
Ischemic cardiomyopathy 3.16
NYHA functional class 1.10
LVEF (%) 1.02
Cardiovascular risk factors
Diabetes 0.60
Hypertension 1.13
Hypercholesterolemia 1.08
Smoking 1.39
Positive family history of CAD 0.87
Medication use
Beta-blockade 1.03
Amiodarone 1.64
ACE-I/ATII antagonist 1.23
Oral anticoagulant 0.61
Statin 1.45
Diuretic 1.13
123-I MIBG imaging
Early H/M ratio 0.35
Late H/M ratio 0.27
Cardiac washout rate (%) 1.02
Early 123-I MIBG SPECT defect score 1.07
Late 123-I MIBG SPECT defect score 1.14
Myocardial perfusion imaging
Rest perfusion defect score 1.02
Stress perfusion defect score 1.03
Summed perfusion difference score 1.09
123-I MIBG/perfusion mismatch score 1.06
*Significant association with appropriate ICD therapy at a level of p
therapy in multivariate analysis.
Abbreviations as in Tables 1 and 2.CD indication (6). rAccordingly, attention has shifted towards improved risk
tratification of patients currently indicated for ICD ther-
py. Recently, the American Heart Association/American
ollege of Cardiology Foundation/Heart Rhythm Society
cientific statement on the noninvasive risk stratification in
atients at risk for sudden arrhythmic death was published,
ndicating that the optimal method for risk stratification is
nclear (15). Although an LVEF of 40% is most com-
only used for stratification of patients at risk for ventric-
lar arrhythmias, it does not allow accurate discrimination
f patients with or without sudden arrhythmic death (15).
oreover, sudden arrhythmic death is often occurred in
atients with an LVEF of 40% (6,15).
Since the majority of patients with documented arrhyth-
ic death are diagnosed with structural heart disease,
redominantly CAD, risk stratification should focus on
urther identification of the underlying substrate for ar-
ariablesf Bas line Variables
d Point)
riable Analysis Multivariable Analysis
CI) p Value HR (95% CI) p Value
1.08) 0.3
4.06) 0.4
3.86) 0.8
10.65) 0.01* 3.85 (1.43–10.37) 0.01†
10.60) 0.06* 2.10 (0.58–7.64) 0.3
2.24) 0.8
1.07) 0.5
2.54) 0.5
2.65) 0.8
2.73) 0.9
3.19) 0.4
2.09) 0.7
2.47) 1.0
4.12) 0.3
4.14) 0.7
1.37) 0.2
3.65) 0.4
4.83) 0.9
3.30) 0.4
2.32) 0.2
1.09) 0.6
1.12) 0.01*
1.20) 0.01* 1.13 (1.05–1.21) 0.01†
1.06) 0.4
1.07) 0.2
1.22) 0.12* 0.93 (0.83–1.05) 0.3
1.09) 0.01* 1.01 (0.97–1.06) 0.5
in univariate analysis. †Significant association with appropriate ICDne Vses o
y En
Univa
R (95%
(0.98–
(0.57–
(0.34–
(1.95–
(0.94–
(0.54–
(0.97–
(0.14–
(0.48–
(0.43–
(0.61–
(0.36–
(0.43–
(0.65–
(0.37–
(0.27–
(0.57–
(0.27–
(0.04–
(0.03–
(0.95–
(1.03–
(1.08–
(0.98–
(0.99–
(0.98–
(1.02–
 0.15hythmic death (15,16). Although the exact mechanisms of
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June 15, 2010:2769–77 Cardiac Denervation Predicts Arrhythmiaentricular arrhythmias have been a matter of debate, it has
een recognized that scar tissue and myocardial ischemia
ay serve as important substrates for ventricular arrhyth-
ias. In acute myocardial infarction, ischemia may serve as
substrate for ventricular arrhythmias by inducing electrical
nstability (17). In chronic myocardial infarction, areas of
low conduction are present that facilitate the development
f reentrant tachycardia (17).
Different imaging techniques (predominantly myocardial
erfusion imaging) have been used to provide information
n the underlying substrate. Borger van der Burg et al. (18)
valuated the occurrence of ventricular arrhythmia and
ardiac death in relation to ischemia, viability, and scar
issue in 156 survivors of sudden arrhythmic death. Extent
f scar tissue and reduced LV function (LVEF 30%) were
ignificantly associated with occurrence of ventricular ar-
hythmias and cardiac death in univariable and multivariable
nalysis. In the present study, ischemia (summed perfusion
ifference score) was significantly associated with appropri-
te ICD therapy in univariable analysis. However, myocar-
ial infarction (resting perfusion defect score) and ischemia
ere not significantly associated with both end points in
ultivariable analysis. One of the potential explanations for
hese findings is the fact that the current study included
atients with nonischemic cardiomyopathy, whereas in the
tudy performed by Borger van der Burg et al. (18), all
atients were diagnosed with significant coronary artery
isease. In the present study, a small amount of myocardial
schemia was observed, which can be explained by the fact
hat these patients received optimal pharmacologic and
evascularization therapy prior to ICD implantation.
The autonomic nervous system may also play an impor-
ant role in the pathogenesis of ventricular arrhythmias
Figure 2 Kaplan-Meier Analysis for Patients With Large or Sma
Kaplan-Meier curve analysis showing the difference in appropriate implantable car
(summed score 26) or small (summed score 26) late 123-iodine metaiodoben7,8). Observational studies have associated the occurrence if ventricular arrhythmias with abnormalities in cardiac
ympathetic innervation (9,10). Although the pathophysio-
ogic mechanisms are unclear, it has been suggested that
enervated, but viable, myocardium may be hypersensitive
o circulating catecholamines. As compared with regions
ith normal cardiac innervation, denervated myocardium
ay respond differently to sympathetic activation with
ncreased automaticity and enhanced triggering (7). In
articular, the border zone of infarct tissue may be predis-
osed to develop reentrant circuits as these regions are
iable, but may have damaged sympathetic nerves. Viable
yocardium may already exhibit areas of denervation (in-
ervation/perfusion mismatch), as sympathetic nerve fibers
re more susceptible to myocardial ischemia than cardiac
issue (19,20).
Recently, the innervation/perfusion mismatch score was
ssessed in 50 patients with LV systolic dysfunction referred
or electrophysiologic testing (10). The innervation/
erfusion mismatch score was not significantly associated
ith inducibility of tachyarrhythmias in univariable and
ultivariable analysis (10). Although the current study
howed that 123-I MIBG/perfusion mismatch score was
ssociated with the occurrence of ventricular arrhythmias in
nivariable analysis, no significant association was found in
ultivariable analysis. The lack of prognostic value of 123-I
IBG/perfusion mismatch score may be related to the
elatively small extent of 123-I MIBG/perfusion mismatch
bserved in the patient population.
isk stratification in heart failure patients with 123-I
IBG imaging. Several studies using 123-I MIBG imag-
ng have demonstrated that abnormalities in global cardiac
nnervation were predictive for overall cardiac mortality in
eart failure patients (21,22). Merlet et al. (22) showed that
-I MIBG SPECT Defect
er-defibrillator therapy (primary end point) between patients with a large
nidine single-photon emission computed tomography (123-I MIBG SPECT) defect.ll 123
diovert
zylguampaired cardiac sympathetic innervation, as assessed with
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Cardiac Denervation Predicts Arrhythmia June 15, 2010:2769–77lanar 123-I MIBG imaging, was associated with adverse
ardiac outcomes in 112 patients with heart failure and a
oor LV function. Over a mean follow-up of 27  20
onths, the only independent predictors for mortality were
ow 123-I MIBG uptake (p  0.01) and LV function (p 
.02). Recently, Agostini et al. (11) confirmed the predictive
alue of cardiac 123-I MIBG imaging in 290 patients with
oderate-to-severe heart failure. Most important, the study
howed that patients with normal 123-I MIBG uptake
howed a significantly higher 2-year event-free survival as
ompared with patients with reduced 123-I MIBG uptake
95% vs. 62%, p  0.01).
23-I MIBG imaging to predict ventricular arrhythmia.
bnormalities in the autonomic nervous system have been
elated to the occurrence of ventricular arrhythmias (9,10).
rora et al. (23) performed a pilot study that evaluated
ardiac sympathetic innervation in 17 patients with ICD
reatment. ICDs were implanted because of sustained ven-
ricular tachycardia or ventricular fibrillation. Patients with
documented ICD discharge showed significantly more
lobal (early H/M ratio) and regional sympathetic denerva-
ion (early and late 123-I MIBG defect score) than patients
ithout an ICD discharge. In addition, Nagahara et al. (24)
valuated in a small study population whether abnormalities
n cardiac sympathetic innervation were related to appro-
riate ICD therapy or lethal cardiac events. During a mean
ollow-up of 15 months, global cardiac sympathetic inner-
ation (assessed with delayed H/M ratio) was independently
ssociated with appropriate ICD therapy.
Tamaki et al. (25) showed that myocardial washout rate
as significantly associated with the occurrence of sudden
rrhythmic death in 106 heart failure patients. In the current
tudy, however, myocardial washout rate was not predictive
or appropriate ICD therapy. One of the explanations for
hese different findings may be the fact that myocardial
ashout rate was significantly lower in the current popula-
ion when compared with the study by Tamaki et al. (25)
lthough both studies enrolled individuals with heart fail-
re and severely reduced LV systolic function, patient’s
edication use was different. The number of patients
eceiving ACE inhibitors (or AT II antagonists) was higher
n the current study (85%) when compared with the study by
amaki et al. (71%) (25). Moreover, patients received
eta-blockade therapy during 123-I MIBG SPECT imag-
ng in this study, whereas Tamaki et al. (25) excluded
atients who had been receiving beta-blocking agents. It has
een demonstrated that the use of ACE inhibitors or
eta-blockers is associated with beneficial modulation of
ardiac sympathetic activity (26,27). Accordingly, changes
n pharmacologic regime may lead to differences in myocar-
ial washout of 123-I MIBG.
The relation between cardiac sympathetic innervation
nd inducibility of ventricular arrhythmias during electro-
hysiologic testing was recently evaluated in 50 patients
ith previous myocardial infarction and reduced LV systolicunction (10). Although no significant association betweenlobal cardiac denervation and inducible ventricular ar-
hythmias was found, regional cardiac denervation was
ignificantly higher in patients with positive electrophysi-
logic tests than patients with negative electrophysiologic
ests. In addition, Mitrani et al. (9) evaluated whether
atients with documented ventricular arrhythmias showed
bnormal sympathetic innervation. Patients with ventricular
achycardia showed significantly more regional sympathetic
enervation as compared with patients without ventricular
achycardia. Likewise, this study demonstrated that regional
ardiac sympathetic denervation derived from late 123-I
IBG SPECT was significantly associated with ventricular
rrhythmias causing appropriate ICD therapy. Moreover,
ate 123-I MIBG SPECT defect score was an independent
redictor for appropriate ICD therapy. Importantly, the risk
or appropriate ICD therapy was 13 times higher in patients
ith a large late 123-I MIBG SPECT defect than patients
ith a small defect.
tudy limitations. Although the current study clearly
emonstrated that cardiac sympathetic denervation on late
23-I MIBG SPECT imaging was predictive for both study
nd points, some limitations need to be considered. In this
tudy, a heterogeneous patient population was enrolled,
ncluding patients with ischemic and nonischemic cardio-
yopathy. Additional studies are needed to establish the
pecific role of 123-I MIBG imaging in these subpopula-
ions. In addition, innervation and perfusion scans were
cored visually, whereas an automatic quantitative approach
ould be preferred. Finally, 123-I MIBG SPECT imaging
n patients with severe LV dysfunction can be limited by
educed myocardial tracer uptake, hampering the acquisi-
ion of tomographic images of the heart. These limitations
ave been compensated by a long acquisition time and the
se of a dual-head SPECT camera equipped with low-
nergy, parallel-hole, high-resolution collimators.
onclusions
ardiac sympathetic denervation on late 123-I MIBG
maging predicts ventricular arrhythmia causing appropriate
CD therapy (primary end point) as well as the composite of
ppropriate ICD therapy or cardiac death (secondary end
oint). Cardiac sympathetic denervation as assessed with
elayed 123-I MIBG SPECT imaging may improve risk
tratification for arrhythmic death in patients who have an
ndication for ICD treatment.
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